MEIHUABIO: The final consideration is 16.8 billion yen, completing the acquisition of the business delivery of amino acids and other products from Kyowa Hakko Bio

Zhitong
2025.07.01 11:08

On July 1st, MEIHUABIO announced that the company and its wholly-owned subsidiary PLUM BIOTECHNOLOGY GROUP PTE.LTD. have completed the business delivery of the "Share and Asset Purchase Agreement" signed with the wholly-owned subsidiary of Kirin Holdings Company, Limited, Kyowa Hakko Bio Co., Ltd

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer